Advertisement
AMGN or BMY or PFE
Which Stock Would AI Choose? Amgen (AMGN) vs. Bristol-Myers Squibb (BMY) vs. Pfizer (PFE) Stock Comparison
Key Takeaways
- Amgen demonstrated robust recent performance with Q2 2026 earnings beats, raised full-year guidance, and strong growth from key products including Repatha and Imdelltra amid pipeline advancements.
- Bristol-Myers Squibb showed steady momentum in its growth portfolio, delivered positive clinical data for Sotyktu, and maintained an attractive dividend yield with upcoming earnings expected later in October.
- Pfizer reported Q2 results that exceeded expectations, raised the midpoint of 2026 revenue guidance, and advanced its non-COVID portfolio while implementing significant cost-saving measures.
- Relative performance highlights contrasts in valuation sensitivity, with AMGN trading at a premium multiple reflecting growth visibility, while BMY and PFE offer higher yields and appear more discounted on forward earnings.
- Sector exposure remains centered on biopharmaceuticals, where patent dynamics, regulatory approvals, and pipeline catalysts influence sentiment across all three names in recent market activity.
- Market positioning varies, with AMGN exhibiting greater resilience in trend consistency despite isolated setbacks, while BMY and PFE balance legacy declines with new product contributions.
Introduction
Amgen, Bristol-Myers Squibb, and Pfizer represent established leaders in the biopharmaceutical sector, each navigating patent expirations, pipeline innovation, and evolving demand for innovative therapies. This comparison examines their recent stock behavior, business drivers, and relative positioning to assist investors and traders evaluating healthcare exposure. Market participants focused on dividend income, growth-oriented biotech plays, or defensive sector allocation may find the analysis relevant when assessing diversification within large-cap pharmaceuticals amid broader economic and regulatory influences.
AMGN Overview and Recent Performance
Amgen Inc. focuses on biotechnology with a portfolio spanning oncology, cardiovascular, and inflammation treatments. In recent weeks, AMGN shares traded near $385, reflecting gains from strong Q2 2026 results that surpassed estimates on both revenue and earnings, prompting raised full-year guidance. Key growth drivers, representing nearly 70% of sales, expanded at a 26% aggregate rate, supported by products such as Repatha and Imdelltra. Positive Phase 3 data for a lung cancer combination and an FDA approval reducing monitoring requirements for Imdelltra bolstered sentiment. A brief pullback followed news of a competitor trial outcome affecting a similar asset, yet overall momentum remained constructive on volume-driven sales and portfolio rotation.
BMY Overview and Recent Performance
Bristol-Myers Squibb Company emphasizes oncology, immunology, and cardiovascular medicines. BMY shares hovered around $63 in recent market activity, supported by Q2 results that exceeded forecasts and continued traction in the growth portfolio. Clinical updates, including durable two-year data for Sotyktu in psoriatic arthritis, contributed to positive sentiment, alongside regular dividend declarations. The company maintains a substantial yield while advancing pipeline assets ahead of third-quarter earnings scheduled for late October. Performance benefited from demand for established therapies offsetting legacy pressures, with year-to-date returns reflecting measured recovery in investor confidence.
PFE Overview and Recent Performance
Pfizer Inc. operates across vaccines, oncology, and internal medicine, with ongoing emphasis on non-COVID products. PFE shares traded near $27.66 recently after Q2 revenues of $15 billion beat expectations and prompted an upward revision to the midpoint of 2026 revenue guidance. Excluding COVID contributions, operational growth reached 5%, aided by launched and acquired assets expanding at 18%. Additional cost savings initiatives totaling approximately $9.7 billion through 2029 and regulatory progress on variant-adapted vaccines supported positioning. Recent weeks featured conference participation and pipeline milestones, with the stock showing resilience amid sector rotation.
Trending AI Robots
Tickeron maintains a curated selection of AI trading bots on its Trending AI Robots page. The platform offers hundreds of AI Trading Bots capable of trading thousands of different tickers, yet only those demonstrating superior alignment with prevailing market conditions earn placement in this focused section. Available bots span a wide range of performance metrics, with historical win rates often between 55% and 75% depending on strategy and timeframe, alongside varying drawdown profiles and trade frequencies. Each bot employs distinct styles, including trend-following, mean-reversion, and momentum approaches across multiple time horizons and ticker sets. Review the live statistics and backtested results to identify suitable options for individual objectives.
Head-to-Head Comparison
Business models differ in emphasis: Amgen leans toward specialized biologics with high-margin growth assets, Bristol-Myers Squibb balances broad oncology leadership with immunology expansion, and Pfizer pursues scale across vaccines and diversified therapeutics. Growth drivers include Amgen’s accelerating volume products, Bristol-Myers Squibb’s new launches offsetting patent losses, and Pfizer’s acquired assets plus cost discipline. Recent momentum favored Amgen’s earnings beats and pipeline news, while Bristol-Myers Squibb and Pfizer delivered steadier, yield-supported advances. Risk factors encompass regulatory and competitive pressures, with Amgen showing sensitivity to cardiovascular trial outcomes, Bristol-Myers Squibb to biosimilar threats, and Pfizer to COVID revenue normalization. Valuation sensitivity appears higher for Amgen at elevated multiples, whereas Bristol-Myers Squibb and Pfizer trade at lower forward earnings ratios with dividend appeal. Market sentiment reflects relative stability in Amgen trends versus recovery narratives at the other two.
Tickeron AI Verdict
Based on observable factors such as earnings consistency, pipeline catalysts, and relative trend stability in recent market activity, Tickeron’s AI would likely assign a probabilistic preference to AMGN for its demonstrated resilience and raised guidance trajectory, though outcomes remain contingent on broader sector dynamics and individual risk parameters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AMGN | BMY | PFE | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 89 | 63 | 38 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 42 Fair valued | 20 Undervalued | |
PROFIT vs RISK RATING 1..100 | 8 | 84 | 100 | |
SMR RATING 1..100 | 15 | 22 | 83 | |
PRICE GROWTH RATING 1..100 | 15 | 48 | 36 | |
P/E GROWTH RATING 1..100 | 27 | 65 | 5 | |
SEASONALITY SCORE 1..100 | 75 | 75 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AMGN's Valuation (8) in the Biotechnology industry is in the same range as PFE (20) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BMY (42) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to PFE’s and somewhat faster than BMY’s over the last 12 months.
AMGN's Profit vs Risk Rating (8) in the Biotechnology industry is significantly better than the same rating for BMY (84) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (100) in the Pharmaceuticals Major industry. This means that AMGN's stock grew significantly faster than BMY’s and significantly faster than PFE’s over the last 12 months.
AMGN's SMR Rating (15) in the Biotechnology industry is in the same range as BMY (22) in the Pharmaceuticals Major industry, and is significantly better than the same rating for PFE (83) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to BMY’s and significantly faster than PFE’s over the last 12 months.
AMGN's Price Growth Rating (15) in the Biotechnology industry is in the same range as PFE (36) in the Pharmaceuticals Major industry, and is somewhat better than the same rating for BMY (48) in the Pharmaceuticals Major industry. This means that AMGN's stock grew similarly to PFE’s and somewhat faster than BMY’s over the last 12 months.
PFE's P/E Growth Rating (5) in the Pharmaceuticals Major industry is in the same range as AMGN (27) in the Biotechnology industry, and is somewhat better than the same rating for BMY (65) in the Pharmaceuticals Major industry. This means that PFE's stock grew similarly to AMGN’s and somewhat faster than BMY’s over the last 12 months.
| AMGN | BMY | PFE | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 74% | 1 day ago 60% | 1 day ago 54% |
| Stochastic ODDS (%) | 1 day ago 59% | 1 day ago 59% | 1 day ago 46% |
| Momentum ODDS (%) | 1 day ago 45% | N/A | 1 day ago 66% |
| MACD ODDS (%) | 1 day ago 71% | N/A | 1 day ago 64% |
| TrendWeek ODDS (%) | 1 day ago 63% | 1 day ago 54% | 1 day ago 54% |
| TrendMonth ODDS (%) | 1 day ago 61% | 1 day ago 55% | 1 day ago 49% |
| Advances ODDS (%) | 2 days ago 61% | 7 days ago 56% | 2 days ago 54% |
| Declines ODDS (%) | 8 days ago 47% | 1 day ago 54% | 9 days ago 56% |
| BollingerBands ODDS (%) | 6 days ago 66% | 1 day ago 68% | 1 day ago 52% |
| Aroon ODDS (%) | 1 day ago 49% | 1 day ago 54% | 1 day ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AMGN’s FA Score shows that 5 FA rating(s) are green while BMY’s FA Score has 1 green FA rating(s), and PFE’s FA Score reflects 2 green FA rating(s).
- AMGN’s FA Score: 5 green, 0 red.
- BMY’s FA Score: 1 green, 4 red.
- PFE’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AMGN’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 4 bullish TA indicator(s), and PFE’s TA Score reflects 2 bullish TA indicator(s).
- AMGN’s TA Score: 6 bullish, 4 bearish.
- BMY’s TA Score: 4 bullish, 4 bearish.
- PFE’s TA Score: 2 bullish, 6 bearish.
Price Growth
AMGN (@Pharmaceuticals: Major) experienced а +2.54% price change this week, while BMY (@Pharmaceuticals: Major) price change was -4.90% , and PFE (@Pharmaceuticals: Major) price fluctuated +3.16% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -5.35%. For the same industry, the average monthly price growth was -7.22%, and the average quarterly price growth was +2.03%.
Reported Earning Dates
AMGN is expected to report earnings on Nov 03, 2026.
BMY is expected to report earnings on Oct 29, 2026.
PFE is expected to report earnings on Nov 03, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-5.35% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
Advertisement
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
PFE and
Correlation & Price change
A.I.dvisor indicates that over the last year, PFE has been loosely correlated with BMY. These tickers have moved in lockstep 55% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then BMY could also see price increases.
| Ticker / NAME | Correlation To PFE | 1D Price Change % | ||
|---|---|---|---|---|
| PFE | 100% | -0.11% | ||
| BMY - PFE | 55% Loosely correlated | -1.58% | ||
| AMGN - PFE | 52% Loosely correlated | -1.13% | ||
| BIIB - PFE | 48% Loosely correlated | -0.22% | ||
| NVS - PFE | 47% Loosely correlated | -0.99% | ||
| SNY - PFE | 47% Loosely correlated | -1.56% | ||
More | ||||